Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ACSL1 | P33121 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | ACSL3 | O95573 | 1/20 | 0.40 |
| ▸ | ACSL6 | Q9UKU0 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2475966 | 1.00 | GAA (0.47) | GAAPKMHRH1EPHX2FAAH | |
| SCHEMBL2475964 | 1.00 | GAA (0.47) | GAAPKMHRH1EPHX2FAAH | |
| SCHEMBL16112031 | 0.85 | KDM1A (0.51) | GAAPKMHRH1EPHX2FAAH | |
| SCHEMBL2471668 | 0.84 | EPHX2 (0.55) | EPHX2FAAHACACBDGAT1 | |
| SCHEMBL2471666 | 0.84 | EPHX2 (0.55) | EPHX2FAAHACACBDGAT1 | |
| SCHEMBL2478658 | 0.84 | ABL1 (0.52) | FAAHMAPTNPC1RAB9AACSL1 | |
| SCHEMBL2478657 | 0.84 | ABL1 (0.52) | FAAHMAPTNPC1RAB9AACSL1 | |
| SCHEMBL2474377 | 0.83 | SLC6A4 (0.48) | EPHX2ALDH1A1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2474378 | 0.83 | SLC6A4 (0.48) | EPHX2ALDH1A1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2472723 | 0.83 | MTNR1A (0.54) | GAAEPHX2MAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4185570-B1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES AS VASOPRESSIN RECEPTOR V1A ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2024-10-09 | — | — | EP | disclosed |
| US-20230202990-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230202990-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4185570-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES AS VASOPRESSIN RECEPTOR V1 A ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2023-05-31 | — | — | EP | disclosed |
| CN-116194441-A | Cyclohexyl-substituted triazoles as vasopressin receptor V1A antagonists | 豪夫迈·罗氏有限公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-2760871-B1 | OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-8828989-B2 | Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists | HOFFMANN-LA ROCHE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2760871-A1 | OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-06 | — | — | EP | disclosed |
| EP-2370441-B1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-09-11 | — | — | EP | disclosed |
| US-8461152-B2 | Arylcyclohexylethers of dihydrotetraazabenzoazulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-06-11 | — | — | US | disclosed |
| WO-2013045373-A1 | OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-04 | — | — | WO | disclosed |
| US-20130079333-A1 | OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-28 | — | — | US | disclosed |
| US-20120225865-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | SCHNIDER PATRICK (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8227458-B2 | Arylcyclohexylethers of dihydrotetraazabenzoazulenes | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2370441-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010060836-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-03 | — | — | WO | disclosed |
| US-20100137286-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | HOFFMANN-LA ROCHE, INC. | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202990-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES | AVPR1A, AVPR1B, AVPR2 | GAA 4526/4885PKM 3194/4885HRH1 480/4885 |
| US-20130079333-A1 | OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | AVPR1A, AVPR1B, ADRA2A | GAA 1935/4885PKM 2973/4885HRH1 201/4885 |
| US-20120225865-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | AVPR1A, AVPR1B, AVPR2 | GAA 4220/4885PKM 3637/4885HRH1 726/4885 |
| US-20100137286-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | AVPR1A, AVPR1B, AVPR2 | GAA 4220/4885PKM 3637/4885HRH1 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.